Open-Label Safety Study of Acoramidis (AG10) in Symptomatic ATTR Participants

Inclusion Criteria:

1. Completed 30 months of the blinded study treatment in Study AG10-301 and the StudyAG10-301 Month 30 visit including assessments and procedures.

2. Have the ability to understand and sign a written informed consent form, which mustbe obtained prior to initiation of study procedures.

3. Female participants of childbearing potential who engage in heterosexual intercoursemust agree to use a highly effective method of contraception beginning withenrollment and continuing for 30 days after the last dose of acoramidis. Femaleparticipants using oral contraceptives must agree to use an additional birth controlmethod. While not considered highly effective, a double-barrier method isacceptable. A male participant who is sexually active with a female of childbearingpotential and has not had a vasectomy must agree to use a double-barrier method ofbirth control.

Exclusion Criteria:

1. Acute myocardial infarction, acute coronary syndrome or coronary revascularizationwithin 90 days prior to Day 1 stroke or transient ischemic attack (TIA) within 90days prior to Day 1.

2. Has hemodynamic instability, that in the judgment of the Investigator, would posetoo great a risk for participation in the study.

3. Has had a heart and/or liver transplant or is on the heart transplantation listwithin the year prior to Day 1

4. Has had implantation of a cardiac mechanical assist device (CMAD) or is scheduledfor implantation of a CMAD

5. Has confirmed diagnosis of light-chain (AL) amyloidosis at any time during StudyAG10-301.

6. Has estimated glomerular filtration rate (eGFR) by modification of diet for renaldisease (MDRD) formula < 15 mL/min/1.73 m2 at Month 27 of Study AG10-301 or at anysubsequent central lab value prior to Day 1.

7. Known hypersensitivity to acoramidis, its metabolites, or formulation excipients.

8. At the end of Study AG10-301 or at Day 1 of Study AG10-304 (or any time during thestudy), participant is on prohibited medication.

9. Females who are pregnant or breastfeeding. A negative urine pregnancy test at theDay 1 visit and at each study visit are required for female participants ofchildbearing potential.

10. In the judgment of the Investigator or Medical Monitor, has any clinically importantongoing medical condition or laboratory abnormality or condition that mightjeopardize the participant's safety, increase their risk from participation, orinterfere with the study.

11. Participation in another interventional clinical trial (with the exception of StudyAG10-301) within 30 days prior to dosing. Participation in observational and/orregistry studies should be discussed with the Medical Monitor.

12. Has any condition that in the opinion of the Investigator or Medical Monitor wouldpreclude compliance with the study protocol such as a history of substance abuse,alcoholism, or a psychiatric condition.